Who
Behrad Derakhshan
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Edgewise Therapeutics.
In numbers
- Trades disclosed
- 57
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $2.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Aug 2021
- Last trade
- 12 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 17 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $95K2,171 at $43.79 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K304 at $44.50 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,667150 at $44.44 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K2,475 at $43.70 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,781 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $95K2,171 at $43.79 | filing |
| 12 Aug 2026filed 14 Aug 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K304 at $44.50 | filing |
News
No headline names them, or the companies they trade most, lately.